JP2024516297A - うつ病の治療のための組成物及び方法 - Google Patents

うつ病の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2024516297A
JP2024516297A JP2023567994A JP2023567994A JP2024516297A JP 2024516297 A JP2024516297 A JP 2024516297A JP 2023567994 A JP2023567994 A JP 2023567994A JP 2023567994 A JP2023567994 A JP 2023567994A JP 2024516297 A JP2024516297 A JP 2024516297A
Authority
JP
Japan
Prior art keywords
aticaplant
patient
anhedonia
treatment
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567994A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022234457A5 (https=
JP2024516297A5 (https=
Inventor
シュミット,マーク
ポポワ,ヴァニナ
サヴィッツ,アダム
メルコテ,ラマ
シー. ドレヴェツ,ワイン
ゴパール,シュリハリ
ペンバートン,ダレル
ラジシェティ,チャクラダール
ケジック,イヴァ
Original Assignee
ヤンセン ファーマシューティカルズ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/307,858 external-priority patent/US11266627B1/en
Priority claimed from US17/670,123 external-priority patent/US12161622B2/en
Application filed by ヤンセン ファーマシューティカルズ,インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ,インコーポレーテッド
Publication of JP2024516297A publication Critical patent/JP2024516297A/ja
Publication of JPWO2022234457A5 publication Critical patent/JPWO2022234457A5/ja
Publication of JP2024516297A5 publication Critical patent/JP2024516297A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
JP2023567994A 2021-05-04 2022-05-03 うつ病の治療のための組成物及び方法 Pending JP2024516297A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17/307,858 2021-05-04
US17/307,858 US11266627B1 (en) 2021-05-04 2021-05-04 Compositions and methods for the treatment of depression
US17/670,123 2022-02-11
US17/670,123 US12161622B2 (en) 2021-05-04 2022-02-11 Compositions and methods for the treatment of depression
US202263313792P 2022-02-25 2022-02-25
US63/313,792 2022-02-25
PCT/IB2022/054085 WO2022234457A1 (en) 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression

Publications (3)

Publication Number Publication Date
JP2024516297A true JP2024516297A (ja) 2024-04-12
JPWO2022234457A5 JPWO2022234457A5 (https=) 2025-05-13
JP2024516297A5 JP2024516297A5 (https=) 2025-05-13

Family

ID=81654924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567994A Pending JP2024516297A (ja) 2021-05-04 2022-05-03 うつ病の治療のための組成物及び方法

Country Status (16)

Country Link
EP (1) EP4333835A1 (https=)
JP (1) JP2024516297A (https=)
KR (1) KR20240004857A (https=)
AU (1) AU2022268720A1 (https=)
BR (1) BR112023023030A2 (https=)
CA (1) CA3219079A1 (https=)
CL (1) CL2023003259A1 (https=)
CO (1) CO2023015571A2 (https=)
IL (1) IL308221A (https=)
JO (1) JOP20230276A1 (https=)
MX (1) MX2023013040A (https=)
PE (1) PE20241784A1 (https=)
PH (1) PH12023552963A1 (https=)
TW (1) TW202313003A (https=)
UY (1) UY39754A (https=)
WO (1) WO2022234457A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2023231493A1 (en) * 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
WO2024216046A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNAL. CLIN. PSYCHIATRY, vol. 33, no. 1, JPN6026010205, 2021, pages 18 - 26, ISSN: 0005818178 *
BIOORG. MED. CHEM. LETT., vol. 24, no. 9, JPN6026010206, 2014, pages 2021 - 2032, ISSN: 0005818179 *
NAT. MED., vol. 26, JPN6026010204, 2020, pages 760 - 768, ISSN: 0005818177 *

Also Published As

Publication number Publication date
CO2023015571A2 (es) 2023-11-30
EP4333835A1 (en) 2024-03-13
IL308221A (en) 2024-01-01
CL2023003259A1 (es) 2024-05-31
WO2022234457A1 (en) 2022-11-10
PH12023552963A1 (en) 2024-03-11
PE20241784A1 (es) 2024-09-06
MX2023013040A (es) 2024-01-05
UY39754A (es) 2022-11-30
KR20240004857A (ko) 2024-01-11
AU2022268720A1 (en) 2023-12-21
TW202313003A (zh) 2023-04-01
BR112023023030A2 (pt) 2024-02-15
CA3219079A1 (en) 2022-11-10
JOP20230276A1 (ar) 2023-11-02

Similar Documents

Publication Publication Date Title
JP2024516297A (ja) うつ病の治療のための組成物及び方法
US11266627B1 (en) Compositions and methods for the treatment of depression
US12150929B2 (en) Compositions and methods for the treatment of depression
CN104519878A (zh) 用于治疗顽固性或难治性抑郁症的艾氯胺酮
EA010430B1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
JP2025508069A (ja) アチカプラントを含む組成物
JP2012522033A (ja) 気分障害の治療における低用量ピパンペロン
AU2016203771A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2025503646A (ja) うつ病の治療のための組成物及び方法
US20250177350A1 (en) Compositions and methods for the treatment of depression
US20240238245A1 (en) Compositions and methods for the treatment of depression
JP2025502098A (ja) うつ病の治療のための組成物及び方法
KR20240132501A (ko) 우울증 치료를 위한 조성물 및 방법
CN117615757A (zh) 用于治疗抑郁症的组合物和方法
EA050800B1 (ru) Композиции и способы лечения депрессии
US20240358693A1 (en) Methods of treating pain
Ozdemir et al. Psychopharmacology of autism spectrum disorder
WO2023023038A1 (en) Treatment compositions and methods
JP2025534727A (ja) 精神神経治療に対する身体的依存を軽減する方法
JP2012533547A (ja) 治療のためのエキソ−s−メカミラミンの方法、使用、及び化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260319